Co-Authors
This is a "connection" page, showing publications co-authored by Michael Ihnat and Lora Bailey-Downs.
Connection Strength
1.121
-
Development and characterization of a preclinical model of breast cancer lung micrometastatic to macrometastatic progression. PLoS One. 2014; 9(5):e98624.
Score: 0.476
-
Targeting dormant micrometastases: rationale, evidence to date and clinical implications. Ther Adv Med Oncol. 2016 Mar; 8(2):126-37.
Score: 0.134
-
Identification of novel drugs to target dormant micrometastases. BMC Cancer. 2015 May 14; 15:404.
Score: 0.127
-
A small molecule with anticancer and antimetastatic activities induces rapid mitochondrial-associated necrosis in breast cancer. J Pharmacol Exp Ther. 2015 May; 353(2):392-404.
Score: 0.125
-
N2-Trimethylacetyl substituted and unsubstituted-N4-phenylsubstituted-6-(2-pyridin-2-ylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines: design, cellular receptor tyrosine kinase inhibitory activities and in vivo evaluation as antiangiogenic, antimetastatic and antitumor agents. Bioorg Med Chem. 2013 Mar 01; 21(5):1312-23.
Score: 0.108
-
AG488 as a therapy against gliomas. Oncotarget. 2017 Sep 22; 8(42):71833-71844.
Score: 0.037
-
The design and discovery of water soluble 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multitargeted receptor tyrosine kinase inhibitors and microtubule targeting antitumor agents. Bioorg Med Chem. 2014 Jul 15; 22(14):3753-72.
Score: 0.030
-
Discovery of antitubulin agents with antiangiogenic activity as single entities with multitarget chemotherapy potential. ACS Med Chem Lett. 2014 May 08; 5(5):480-4.
Score: 0.029
-
Solid phase synthesis and biological evaluation of probestin as an angiogenesis inhibitor. Bioorg Med Chem Lett. 2013 Jun 15; 23(12):3561-4.
Score: 0.028
-
Novel tricyclic indeno[2,1-d]pyrimidines with dual antiangiogenic and cytotoxic activities as potent antitumor agents. Bioorg Med Chem. 2012 Jul 15; 20(14):4217-25.
Score: 0.026